Enrique Gomez-Pomar

Enrique Gomez-Pomar

Auto-generated profile, based on publicly available information

Enrique Gomez-Pomar

Division of Neonatology, Department of Pediatrics, University of Kentucky, Lexington, KY, United States

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2018 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
EGEnrique Gomez-Pomar
Enrique Gomez-Pomar
RBRobert Blubaugh
Robert Blubaugh

22 February 2018 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
EGEnrique Gomez-Pomar
Enrique Gomez-Pomar
LFLoretta P. Finnegan
Loretta P. Finnegan
Neonatal abstinence syndrome (NAS) refers to a constellation of signs that are present in some newborn infants resulting from the abrupt cessation of passive transfer of maternal opioids used during pregnancy. The classic NAS refers to infants born to mothers who used opioids during pregnancy, but the term has broadened to include infants whose mothers have used or abused other psychoactive substances during pregnancy that contribute to the expression of the syndrome. Pregnant women who use opioids do so illicitly, and/or as medically prescribed for pain relief, and/or as medication assisted treatment for opioid dependence. The first case of NAS in infants and the subsequent treatment (or lack thereof) was reported in 1875 and was called Congenital Morphinism. By 2012, the incidence of NAS increased to more than 30 per 1,000 hospital live births, along with an increase in the number of infants being treated pharmacologically for NAS, resulting in an increase in the length of stay and healthcare expenses. We present historical references on NAS, the various factors and events that led to its increasing prevalence and today’s current epidemic. We also review the current tools to assess infants with NAS and treatment options in its management.

27 September 2017 in BMJ Open
Verified
Journal Article
Open access
PDF file
EPEnrique Gomez Pomar
Enrique Gomez Pomar
LFLoretta P Finnegan
Loretta P Finnegan
LDLori Devlin
Lori Devlin
HBHenrietta Bada
Henrietta Bada
VCVanessa A Concina
Vanessa A Concina
PWPhilip M Westgate
Philip M Westgate
Objective To develop a simplified Finnegan Neonatal Abstinence Scoring System (sFNAS) that will highly correlate with scores ≥8 and ≥12 in infants being assessed with the FNAS. Design, setting and participants This is a retrospective analysis involving 367 patients admitted to two level IV neonatal intensive care units with a total of 40 294 observations. Inclusion criteria included neonates with gestational age ≥37 0/7 weeks, who are being assessed for neonatal abstinence syndrome (NAS) using the FNAS. Infants with a gestational age <37 weeks were excluded. Methods A linear regression model based on the original FNAS data from one institution was developed to determine optimal values for each item in the sFNAS. A backward elimination approach was used, removing the items that contributed least to the Pearson’s correlation. The sFNAS was then cross-validated with data from a second institution. Results Pearson’s correlation between the proposed sFNAS and the FNAS was 0.914. The optimal treatment cut-off values for the sFNAS were 6 and 10 to predict FNAS scores ≥8 and ≥12, respectively. The sensitivity and specificity of these cut-off values to detect FNAS scores ≥8 and ≥12 were 0.888 and 0.883 for a cut-off of 6, and 0.637 and 0.992 for a cut-off of 10, respectively. The sFNAS cross-validation resulted in a Pearson’s correlation of 0.908, sensitivity and specificity of 0.860 and 0.873 for a cut-off of 6, and 0.525 and 0.986 for a cut-off of 10, respectively. Conclusion The sFNAS has a high statistical correlation with the FNAS, and it is cross-validated for the assessment of infants with NAS. It has excellent specificity and negative predictive value for identifying infants with FNAS scores ≥8 and ≥12.

12 December 2018 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
EPEnrique Gomez Pomar
Enrique Gomez Pomar
VCVanessa A. Concina
Vanessa A. Concina
ASAaron Samide
Aaron Samide
PWPhilip M. Westgate
Philip M. Westgate
HBHenrietta S. Bada
Henrietta S. Bada
Objectives: To compare the Shennan's and the consensus definition of Bronchopulmonary Dysplasia (BPD) from the National Institutes of Health (NIH) workshop and analyze specific risk factors associated with each definition. Study design: Retrospective analysis of records of 274 infants admitted to a level IV intensive care unit. Infants were classified as having BPD or no BPD by both definitions. Differences in incidence and risk factors were analyzed. Statistical methods included descriptive statistics, comparative tests, and marginal logistic regression modeling. Results: The estimated difference in prevalence was 32% [95% CI: (26%, 37%), (p < 0.0001)] between both criteria. The prevalence of BPD was 80% higher based on the NIH criteria [RR = 1.80; 95% CI: (1.58, 2.06)]. Infants with no BPD by the Shennan definition were breathing room air with or without positive or continuous pressure support and were most likely to be discharged home on oxygen [OR = 4.47, 95% CI: (1.20, 16.61), p = 0.03]. Gestational age, birth weight, and 1-min Apgar score predicted BPD by both definitions. Chorioamnionitis increased the risk of BPD by the Shennan definition but was associated with lower risk by the NIH criteria. IUGR was associated with BPD by the Shennan definition and with severe BPD by the NIH criteria. Conclusion: Compared to the Shennan's definition, the NIH consensus identified 80% more infants with BPD and is a better predictor of oxygen requirement at discharge. Until a new better criteria is develop, the NIH consensus definition should be used across centers.

1 April 2020 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
LDLori A. Devlin
Lori A. Devlin
JBJanis L. Breeze
Janis L. Breeze
NTNorma Terrin
Norma Terrin
EPEnrique Gomez Pomar
Enrique Gomez Pomar
HBHenrietta Bada
Henrietta Bada
JDJonathan M. Davis
Jonathan M. Davis
The medical and nonmedical use of opioids in the United States has increased significantly during the last decade.1-4 Opioid use disorder (OUD) during pregnancy increased from 1.5 per 1000 live births to 6.5 per 1000 live births between 1999 and 2014.5 Antenatal exposure to opioids has led to a 5-fold rise in the incidence of neonatal abstinence syndrome (NAS) between 2004 and 2014, a number that continues to increase.6,7 Neonatal abstinence syndrome is a withdrawal syndrome that occurs after the interruption of the passive transfer of maternal opioids at the time of birth. The diagnosis of NAS is dependent on the presence of key signs of withdrawal, with severity being highly variable.8,9 Every neonate exposed to opioids in utero is somewhere along the continuum of withdrawal. While some neonates have mild signs and normal physiologic functions, others have more severe NAS that requires pharmacologic treatment to avoid major complications.10 Differences in the expression of NAS is associated with many factors, including the type(s) of opioid exposure, coexposure with other illicit drugs and/or psychotropic medications, genetic and epigenetic variability, the gestational age and sex of the neonate, breastfeeding, and parental engagement.11-17

10 October 2017 in American Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
EHEmily Hatfield
Emily Hatfield
KGKaren Garlitz
Karen Garlitz
PWPhilip M. Westgate
Philip M. Westgate
HBHenrietta S. Bada
Henrietta S. Bada
EGEnrique Gomez-Pomar
Enrique Gomez-Pomar
Objective Vitamin E deficiency in premature infants has been associated with hemolytic anemia. Its incidence decreased after the supplementation of preterm formulas and parenteral nutrition with vitamin E. Despite this, some infants still develop hemolytic anemia and receive vitamin E. Design Retrospective analysis of 70 infants admitted to a level IV intensive care unit and who developed hemolytic anemia and were treated with vitamin E. Infants were classified into two groups based on whether or not they responded to vitamin E therapy. Statistical methods included the use of descriptive statistics and marginal logistic regression models. Results Low hematocrit and reticulocytosis before vitamin E administration were associated with adequate response to treatment. Thrombocytosis, iron treatment (duration and dose), gestational age, birth weight, and type of feedings were not. Infants who received a short duration of parenteral nutrition and were on oxygen responded to vitamin E therapy. Infants with a hematocrit ≤ 26% and reticulocyte of 36.1% were more likely to respond to vitamin E. Conclusion Although formulas and parenteral nutrition are supplemented with vitamin E; some preterm infants may still develop hemolytic anemia. Those with anemia, reticulocytosis, and oxygen requirement may benefit from additional vitamin E. None.